Evidence map›Paper›PMID 35776836›Full record

ArticleHuman vaccines & immunotherapeutics2022

Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.

Nussara Pakvisal, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Nassamon Wanlapakorn, Ritthideach Yorsaeng, Yong Poovorawan, Piyapoom Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn and 3 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nussara PakvisalDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Panot SainamthipDepartment of Pharmacology, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Nattaya TeeyapunDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Sutima LuangdilokDepartment of Biochemistry, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Nassamon WanlapakornCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Ritthideach YorsaengCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Yong PoovorawanCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Piyapoom PakvisalDepartment of Medicine, Police General Hospital, Bangkok, Thailand.
Thiti SusiriwatananontDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Nicha ZungsontipornDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Virote SriuranpongDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Suebpong TanasanvimonDivision of Medical Oncology, Department of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Passakorn WanchaijiraboonPhrapokklao Cancer Center of Excellence, Phrapokklao Clinical Research center, Phrapokklao Genomic Laboratories, Phrapokklao Hospital, Chantaburi, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study aimed to evaluate vaccine-related adverse events (VRAEs) following ChAdOx1-nCoV-19 vaccine in solid cancer patients receiving treatment compared to healthy controls. 399 cancer patients and 90 healthy volunteers were enrolled. In the overall population, the incidence of VRAEs was significantly lower in cancer patients than in healthy volunteers (57% vs 80%,

Indexed as

COVID-19NeoplasmsChAdOx1 nCoV-19COVID-19 VaccinesHumansMiddle AgedVaccinationChAdOx1 nCoV-19COVID-19 VaccinesAdverse eventsAZD1222Cancer treatmentChAdOx1-nCoV-19Covid-19 vaccineMalignancy patientsSafety

Identifiers

PMID35776836
PMCPMC9746493

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.